购物车
- 全部删除
- 您的购物车当前为空
Olendalizumab (ALXN1007)为源自小鼠的人源化IgG2-G4-κ抗体,专一靶向补体蛋白C5a(Ki=60 pM),用于探究冠状病毒引发的补体介导疾病,并针对补体炎症通路。
Olendalizumab (ALXN1007)为源自小鼠的人源化IgG2-G4-κ抗体,专一靶向补体蛋白C5a(Ki=60 pM),用于探究冠状病毒引发的补体介导疾病,并针对补体炎症通路。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
5 mg | 询价 | 期货 |
产品描述 | Olendalizumab (ALXN1007), a humanized IgG2-G4-κ antibody derived from mice, specifically targets Complement protein C5a with a binding affinity (K i) of 60 pM. This compound is designed to inhibit the complement inflammatory pathway. Additionally, olendalizumab is utilized in the research of complement-mediated disorders triggered by the coronavirus [1] [2]. |
CAS No. | 2210314-30-8 |
存储 | Shipping with blue ice. |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容